- Home
- GILD vs MUFG Comparison
GILD vs MUFG Comparison
Compare GILD & MUFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | MUFG |
|---|---|---|
| Founded | 1987 | 1880 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9B | 179.9B |
| IPO Year | 1992 | 2001 |
Fundamental Metrics
Financial Performance| Metric | GILD | MUFG |
|---|---|---|
| Price | $141.36 | $18.13 |
| Analyst Decision | Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $129.10 | N/A |
| AVG Volume (30 Days) | ★ 6.6M | 3.1M |
| Earning Date | 02-10-2026 | 01-30-2026 |
| Dividend Yield | ★ 2.29% | 2.27% |
| EPS Growth | ★ 6514.05 | N/A |
| EPS | ★ 6.42 | 0.76 |
| Revenue | $29,087,000,000.00 | ★ $38,565,096,137.00 |
| Revenue This Year | $3.66 | $2.23 |
| Revenue Next Year | $3.32 | $7.31 |
| P/E Ratio | ★ $21.45 | $23.19 |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $93.10 | $10.46 |
| 52 Week High | $138.03 | $18.90 |
Technical Indicators
Market Signals| Indicator | GILD | MUFG |
|---|---|---|
| Relative Strength Index (RSI) | 75.05 | 65.88 |
| Support Level | $120.95 | $17.77 |
| Resistance Level | $124.48 | $18.90 |
| Average True Range (ATR) | 4.14 | 0.23 |
| MACD | 1.99 | 0.01 |
| Stochastic Oscillator | 97.05 | 68.23 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.